Literature DB >> 2271559

Protein chemical and kinetic characterization of recombinant porcine ribonuclease inhibitor expressed in Saccharomyces cerevisiae.

A M Vicentini1, B Kieffer, R Matthies, B Meyhack, B A Hemmings, S R Stone, J Hofsteenge.   

Abstract

A cDNA encoding porcine ribonuclease inhibitor was used to express this protein in yeast under control of the PHO5 promoter. The recombinant protein was purified to homogeneity with a yield of 0.2 mg/g of yeast cells (wet weight) and was found to be indistinguishable from the inhibitor isolated from porcine liver on the basis of the following criteria: the amino acid composition, the number of free sulfhydryl groups, the molecular weight of the native and the denatured protein, peptide mapping, and amino acid sequence analysis of the N- and C-terminal regions of the protein. A simple method was developed for measuring accurately the slow, tight-biding kinetics of the inhibition of ribonuclease by ribonuclease inhibitor. From the dependence of the observed inhibition constant on the substrate concentration, it could be concluded that RI was competitive with the substrate UpA. The dependence of the observed association rate constant on the substrate concentration was consistent with a two-step mechanism in which the substrate only competed in the second (isomerization) step. The values for the inhibition constant for the inhibition of RNase by the recombinant inhibitor, 67 fM, the association rate constant, 1.5 x 10(8) M-1.s-1, and the dissociation rate constant, 8.3 x 10(-6) s-1, were in good agreement with those obtained for the porcine liver RNase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2271559     DOI: 10.1021/bi00489a046

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action.

Authors:  S Di Gaetano; G D'alessio; R Piccoli
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

Review 2.  Cancer chemotherapy--ribonucleases to the rescue.

Authors:  P A Leland; R T Raines
Journal:  Chem Biol       Date:  2001-05

3.  The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity.

Authors:  Pere Tubert; Montserrat Rodríguez; Marc Ribó; Antoni Benito; Maria Vilanova
Journal:  Invest New Drugs       Date:  2010-03-30       Impact factor: 3.850

Review 4.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

5.  Analysis of the interactions of ribonuclease inhibitor with kanamycin.

Authors:  Zhanli Wang; Liangren Zhang; Jingfen Lu; Lihe Zhang
Journal:  J Mol Model       Date:  2005-01-12       Impact factor: 1.810

6.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

7.  Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway.

Authors:  Marcia C Haigis; Ronald T Raines
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

8.  Selective abolition of pancreatic RNase binding to its inhibitor protein.

Authors:  Kapil Kumar; Michael Brady; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-17       Impact factor: 11.205

9.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 10.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.